|
Variables
|
Unadjusted analysis
|
Adjusted analysis
|
|---|
|
OR (95% CI)
|
P value
|
OR (95% CI)
|
P value
|
|---|
|
Age
|
1.00 (0.97–1.03)
|
0.99
|
1.01 (0.97–1.06)
|
0.56
|
|
Disease durationa
|
2.28 (0.93–5.59)
|
0.07
|
1.81 (0.48–6.85)
|
0.39
|
|
BMI
|
1.08 (0.97–1.20)
|
0.15
|
1.07 (0.93–1.24)
|
0.34
|
|
DAS28-ESRb
|
10.5 (3.40–32.1)
|
<0.05
|
6.88 (1.84–25.7)
|
<0.05
|
|
RF positive
|
2.39 (0.64–8.94)
|
0.19
|
1.82 (0.40–8.37)
|
0.44
|
|
Glucocorticoid
|
4.59 (1.48–14.2)
|
<0.05
|
8.24 (1.77–38.4)
|
<0.05
|
|
Biologic DMARDs
|
4.21 (1.86–9.51)
|
<0.05
|
1.89 (0.54–6.64)
|
0.32
|
|
RA involvement
|
|
Forefoot
|
0.72 (0.30–1.75)
|
0.47
|
0.85 (0.28–2.60)
|
0.77
|
|
Midfoot
|
6.00 (2.28–15.8)
|
<0.05
|
5.81 (1.41–23.9)
|
<0.05
|
|
Hindfoot
|
2.85 (1.30–6.25)
|
<0.05
|
1.24 (0.41–3.76)
|
0.71
|
|
Ankle
|
0.66 (0.07–6.54)
|
0.72
|
0.29 (0.02–5.73)
|
0.42
|
|
Foot deformity
|
|
Hallux valgus
|
1.33 (0.54–3.28)
|
0.53
|
0.68 (0.19–2.51)
|
0.56
|
|
Metatarsus primus varus
|
0.89 (0.39–2.03)
|
0.78
|
0.93 (0.30–2.85)
|
0.90
|
|
Pes planus
|
1.00 (0.18–5.71)
|
1.00
|
0.50 (0.05–5.22)
|
0.56
|
-
BMI body mass index, DAS28 disease activity score 28, DMARDs disease-modifying antirheumatic drugs, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, OR odds ratio, RF rheumatoid factor
-
aDisease duration was divided into two groups based on a cut-off of 2 years
-
bDAS28-ESR was divided into two groups, remission to low disease activity (DAS28-ESR ≤ 3.2) and moderate to high disease activity (DAS28-ESR > 3.2)
